A new report says that exposure to iodinated contrast media during imaging procedures is associated with changes in thyroid function, and increased risk of developing hyperthyroidism. The report appears in the January 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
"Iodinated contrast media (ICM) are commonly administered pharmaceutical agents," the authors write as background information. ICM are frequently used in scans and imaging procedures such as cardiac catheterization and computed tomography (CT scans). "Although certain complications of ICM (e.g., contrast-induced nephropathy) have been extensively studied, there has been little examination of the effect of ICM on thyroid function."
Connie M. Rhee, M.D., and colleagues from Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, examined data from patients treated between January 1990 and June 2010 who did not have preexisting hyperthyroidism or hypothyroidism. Patients were matched with euthyroid (normal thyroid function) controls, and exposure to iodinated contrast media was assessed using claims data.
Secondary analysis indicated an association between iodinated contrast media exposure and incident overt (clinical; diagnosed based on characteristic clinical features) hypothyrodism and incident overt (clinical) hyperthyroidism.
"In summary, these data support association between ICM exposure and incident hyperthyroidism, incident overt hyperthyroidism and incident overt hypothyroidism," the authors conclude. "Given the pervasive use of ICM in contemporary practice and the known sequelae of thyroid functional derangements, further studies are needed to confirm and evaluate generalizability of these findings, to establish causality and to explore mechanisms."
(Arch Intern Med. 2012;172:153-159. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: This study was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. An author also receives research support from Veracyte, Inc., and Asuragen, Inc. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Invited Commentary: Iodine-Induced Thyroid Dysfunction
In an accompanying invited commentary, Elizabeth N. Pearce, M.D., M.Sc., of Boston University School of Medicine writes that Rhee et al "describe significant associations between contrast exposure and the development of hyperthyroidism. While no overall association exists between contrast exposure and all forms of hypothyroidism, an association was noted when cases were restricted to those with overt hypothyroidism."
"These data represent an important contribution to our knowledge about a clinically relevant and understudied area," Dr. Pearce writes. "Rhee et al have demonstrated that a relatively large proportion of individuals who developed iodine-induced thyroid dysfunction were not known to have underlying risk factors. Therefore, patients who may be particularly unable to tolerate thyroid dysfunction, such as those with underlying unstable cardiovascular disease, are also good candidates for monitoring of thyroid function after iodine exposure."
(Arch Intern Med. 2012;172:159-161. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.